Structural mechanism for statin inhibition of HMG-CoA reductase

被引:1205
|
作者
Istvan, ES
Deisenhofer, J [1 ]
机构
[1] Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA
[2] Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA
关键词
D O I
10.1126/science.1059344
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase (HMGR) catalyzes the committed step in cholesterol biosynthesis. Statins are HMGR inhibitors with inhibition constant values in the nanomolar range that effectively lower serum cholesterol levels and are widely prescribed in the treatment of hypercholesterolemia. We have determined structures of the catalytic portion of human HMGR complexed with six different statins. The statins occupy a portion of the binding site of HMG-CoA, thus blocking access of this substrate to the active site. Near the carboxyl terminus of HMGR, several catalytically relevant residues are disordered in the enzyme-statin complexes. If these residues were not flexible, they would sterically hinder statin binding.
引用
收藏
页码:1160 / 1164
页数:5
相关论文
共 50 条
  • [1] Statin Inhibition of HMG-CoA Reductase by Quantum Biochemistry Computations
    Fulco, U. L.
    Albuquerque, E. L.
    da Silva, L. R.
    [J]. 29TH SOUTHERN BIOMEDICAL ENGINEERING CONFERENCE (SBEC 2013), 2013, : 159 - +
  • [2] Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase
    Wurtz, Peter
    Wang, Qin
    Soininen, Pasi
    Kangas, Antti J.
    Fatemifar, Ghazaleh
    Tynkkynen, Tuulia
    Tiainen, Mika
    Perola, Markus
    Tillin, Therese
    Hughes, Alun D.
    Mantyselka, Pekka
    Kahonen, Mika
    Lehtimaki, Terho
    Sattar, Naveed
    Hingorani, Aroon D.
    Casas, Juan-Pablo
    Salomaa, Veikko
    Kivimaki, Mika
    Jarvelin, Marjo-Riitta
    Smith, George Davey
    Vanhala, Mauno
    Lawlor, Debbie A.
    Raitakari, Olli T.
    Chaturvedi, Nish
    Kettunen, Johannes
    Ala-Korpela, Mika
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (10) : 1200 - 1210
  • [3] Statin inhibition of HMG-CoA reductase: a 3-dimensional view
    Istvan, E
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2003, 4 (01) : 3 - 8
  • [4] Explaining statin inhibition effectiveness of HMG-CoA reductase by quantum biochemistry computations
    da Costa, Roner F.
    Freire, Valder N.
    Bezerra, Eveline M.
    Cavada, Benildo S.
    Caetano, Ewerton W. S.
    de Lima Filho, Jose L.
    Albuquerque, Eudenilson L.
    [J]. PHYSICAL CHEMISTRY CHEMICAL PHYSICS, 2012, 14 (04) : 1389 - 1398
  • [5] Newer HMG-CoA reductase inhibitor (statin) therapies
    Brinton, EA
    [J]. CLINICAL CARDIOLOGY, 2001, 24 (07) : II10 - II13
  • [6] INHIBITION OF DEGRADATION OF HMG-COA REDUCTASE BY MEVINOLIN
    SINENSKY, M
    LOGEL, J
    [J]. JOURNAL OF LIPID RESEARCH, 1983, 24 (10) : 1413 - 1413
  • [7] The Increasingly Complex Mechanism of HMG-CoA Reductase
    Haines, Brandon E.
    Wiest, Olaf
    Stauffacher, Cynthia V.
    [J]. ACCOUNTS OF CHEMICAL RESEARCH, 2013, 46 (11) : 2416 - 2426
  • [9] New structural insight into HMG-CoA reductase mechanism and cofactor specificity
    Kung, Yan
    [J]. ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2018, 74 : A65 - A65
  • [10] INHIBITION OF HMG-COA REDUCTASE BY DERIVATIVES OF GLYCYRRHETIC ACID
    JETT, C
    MILLER, JE
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1977, 174 (SEP): : 102 - 102